The Biotech Press Lounge at the IZB
Mit dem Laden des Videos akzeptieren Sie die Datenschutzerklärung von YouTube.
Mehr erfahren
March 16, 2023
Impulse Talks
Dr. Karl Nägler
Managing Partner, Wellington Partners
Topic:
Drug therapy, state 2043
Heimo Adamski
CEO 4GENE GmbH
Topic:
Improved molecules that change the world
Platform technology for “Improved Molecules” , in the fields of cosmetics, pharmaceuticals and industrial safety.
Dr. Daniel Reichart
Postdoctoral Fellow Department of Genetic Harvard Medical School und XTransplant Consultant
Topic:
Next generation diagnostics and therapeutics in cardiovascular medicine
Dr. Mathias Falcenberg
Executive Director, Head Search & Evaluation, Merck Healthcare
Welcome & Moderation
Dr. Peter Hanns Zobel,
Managing Director of the IZB
Anouschka Horn
Bavarian Television
Mit dem Laden des Videos akzeptieren Sie die Datenschutzerklärung von YouTube.
Mehr erfahren
September 30, 2022
Location
In the Faculty Club G2B (Gateway to Biotech)
in the Innovation and Startup Center Biotechnology
Am Klopferspitz 21
82152 Planegg/Martinsried
Registration
Please register directly with Susanne Simon,
Head of Press and Public Relations IZB:
ed.enilno-bzi@nomis
Keynote speeches on current topics with
followed by a business lunch
The number of participants is limited to 60.
Impulse talks
Prof. Dr. Markus M. Lerch
Medical Director, Chairman of the Board, LMU Klinikum in Großhadern
Topic
Biotechnology and university medicine – an area of tension
Chantal Friebertshäuser
General Manager, MSD Deutschland
Topic
More lifetime gain – digitization, Rethinking
Prevention and Cooperation
PhD Gregory Fanning
CEO SCG Cell Therapy GmbH
Topic
Immune therapy for pathogen related cancers
Dr. Karl Nägler
Managing Partner, Wellington Partners
Topic
Drug Therapy, Stand 2042
Welcome & Moderation
Dr. Peter Hanns Zobel,
Managing Director, IZB
Anouschka Horn
Bavarian television
Mit dem Laden des Videos akzeptieren Sie die Datenschutzerklärung von YouTube.
Mehr erfahren
SAVE THE DATE: March 23, 2022
Location – Hybrid-Event
Presseclub München e.V.
Marienplatz 22
80331 München
Anmeldung
Insgesamt können wir 30 Gäste vor Ort einladen.
Bitte melden Sie sich dazu direkt bei Susanne Simon,
Leitung Presse- und Öffentlichkeitsarbeit IZB, an:
ed.enilno-bzi@nomis
Registrierung für Gäste im Presseclub
10.00 Uhr
Streaming
Das Event können Sie auch auf der Website des Presseclubs verfolgen:
https://www.youtube.com/c/PresseClubMünchen-e-V
oder auf dem LinkedIn-Profil des IZB:
https://www.linkedin.com/company/innovation-and-startup-center-for-biotechnology-izb/
Corona
Es gilt 2G plus. Schnelltests können mitgebracht oder vor Ort durchgeführt werden.
Die Referenten
Dr. Malte Peters
Chief Research and Development Officer MorphoSys AG
Thema:
MorphoSys – Unser Bestreben, ein führendes Unternehmen in der Hämatologie und Onkologie zu werden
Heinrich Moisa
Vorsitzender der Geschäftsführung Novartis Deutschland & Geschäftsführer Novartis Onkologie
Thema:
Innovation durch Vernetzung: Spitzenforschung gemeinsam gestalten
Prof. Dr. Ulrike Protzer
Direktorin Institut für Virologie, TU München, Direktorin Helmholtz Zentrum München, Co-Founder SCG Cell Therapie GmbH
Thema:
Immuntherapie für Hepatitis B und das hepatoceluläre Karzinom
Dr. Sebastian Mangold
Geschäftsführer mk2 Biotechnologies
Thema:
Entwicklung und Produktion innovativer Peptide als Game-Changer im Bereich der Krankheitstherapie und Pharmazeutika
Prof. Dr. Eckhard Wolf
Leiter des Sonderforschungsbereiches Xenotransplantation, Genzentrum LMU
Thema:
Genetisch modifizierte Schweine als Spender für die Xenotransplantation
Begrüßung & Moderation
Dr. Peter Hanns Zobel,
Geschäftsführer, IZB
Anouschka Horn
Bayerisches Fernsehen
Image galleries of the Biotech Press Lounge at the IZB
We have been able to win these top-class speakers and presenters for the Press Lounge in the past:
Speakers
Andreas Huber (Scientific Director Life Science and Senior Investment Manager, Bayern Kapital)
Investing in Life Sciences
Jason Loveridge (CEO, 4SC)
Domatinostat—Boosting Immunotherapy in Cancer
Michael Crowley (Head Business Development for Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., Basel)
Partnering in a new era—How are we collectively driving innovation?
Moderation
Jo Schilling (Editor, Technology Review)
Speakers
Prof. Dr. Dr. h.c. Bruno Reichart (Former Cardiac Surgeon, Co-Speaker DFG Transregio Xenotransplantation, Clinic ot the University Munich)
Consistent success in life-supporting porcine cardiac transplantation
Dr. Michael Almstetter (CEO, Origenis GmbH)
What can be learned from the progress in oncology for new treatments in Alzheimer and Parkinson Diseases?
Dr. Joachim Vogt (Director Search and Evaluation (S&E), Western Europe, AbbVie Deutschland GmbH & Co. KG)
– Partnering with a global innovation driven biopharmaceutical company
Sebastian Grabert (Director – Germany Representative, EURONEXT N.V.)
Strengthening the european Life Science sector through stock exchanges
Moderation
Dr. Martin Laqua (Senior Editor, transkript)
Speakers
Dr. Hubert Birner (Managing Partner, TVM Capital GmbH)
Sleepless in Munich – a clinical phenomenon in the VC industry
Phil L’Huillier (Head of Business Development Europe & Middle East, MSD Innovation Hub)
Partnering with MSD and plans for our new European Discovery Research Center in UK
Dr. Ali Ertürk (Group Leader, Institue for Stroke and Dementia Research (ISD, LMU München)
Transformative technologies to accelerate biomedical research and treat deadly diseases in our life time
Moderation
Eva Müller (Journalist, Manager Magazin)
Speakers
Thomas Hegendoerfer (New Venture Lead, Johnson & Johnson Innovation)
Fostering the external innovation landscape for breakthrough therapies
Dr. Marion Jung (CEO, ChromoTek GmbH)
ChromoTek is revolutionizing research worldwide with innovative antibody formats
Dr. Karsten Kissel (Director Medical Affairs Germany, Gilead Sciences GmbH)
Innovative therapies from research to patient: cell therapies as major progress in oncology
Moderation
Jochen Niehaus (Chief Editor, Focus GESUNDHEIT)
Speakers
Ph.D. Timothy Luker (Senior Director, Emerging Technology & Innovation, Business Development, Eli Lilly)
External innovation at Eli Lilly
Prof. Dr. Patrick Baeuerle (Managing Director, MPM Capital)
Cullinan Oncology: A novel way to invest in cancer drugs
Stephen S. Yoder (CEO, Pieris Pharmaceuticals Inc.)
Challenges and opportunities in building a sustainable innovative biotech enterprise in Germany and beyond
Moderation
Joachim Müller-Jung (Chief Nature and Science Editor, FAZ)
Speakers
Prof. Dr. Stefan Jaroch (Head of External Innovation Technologies, Bayer Pharma AG)
Open Innovation in Drug Discovery
Peter Homberg (Partner, Head of German Life Science Practice, DENTONS Europe LLP)
Soft-Factors – Importance for successful Exit-Transactions
PhD. Mikkel Noerholm (Vice President of Product Development, Exosome Diagnostics)
A non-invasive test to avoid unnecessary biopsy: ExoDx Prostate (IntelliScore)
Moderation
Evelyn Warner (Chief Editor, Labiotech.eu)
Speakers
Dr. Markus Dangl (Senior Vice President Research and Pre-Clinical Development, Medigene AG)
New Horizons for Medigene as an Immunotherapy Company
Paola Casarosa (Corporate Vice President Therapeutic, Boehringer Ingelheim)
New Horizons for Medigene as an Immunotherapy Company
Dr. jens Altrichter (COO, Leukocare AG)
The importance of advanced formulation in biopharmaceutical product development
Moderation
Julia Groß (Journalist, Euro am Sonntag)
Speakers
Dr. Markus Enzelberger (Interim-CSO, MorphoSys AG)
Will the first MorphoSys antibody be on the market soon?
Dr. Christian Jung (Principal, Wellington Partners)
Update to the Life Science Venture Capital Market
Dr. Christian Schetter (Managing Director, Rigontec GmbH)
Positioning a German biotech in the global immuno-oncology sector
Moderation
Bettina Reckter (Editor, VDI Nachrichten)
Speakers
Holger Reithinger (General Manager, Forbion Capital Partners)
What can we learn from the Americans about financing rounds and what should we rather leave alone?
Jens Klein (CEO, AMSilk GmbH)
Adidas and AMSilk present the first sport shoes made out of natural silk biopolymers
Dr. Matthias Kromayer (Board Member, MIG AG)
Why biotechs sometimes fail and what can one do to prevent it
Moderation
Bettina Reckter (Editor, VDI Nachrichten)
Speakers
Dr. Steffan Kropff (Executive Medical Director, Amgen GmbH)
Therapy advance in cardiology through biotech
Martin Spitznagel (CEO, Dust Biosolutions)
How to turn dust into stone with the help of bacteria
Dr. Rainer Schubbert (Head of operations Applied Genomicas, Eurofins Genomics)
New genomic method for blood analysis: Liquid Biopsies
Moderation
Matthias Renz (Publishing Management, Venture Capital Magazin)
Speakers
Dr. Frank Mathias (Chairman vfa bio, CEO, Rentschler Biotechnologie GmbH)
Medical biotechnology in Germany – Current figures and data
Prof. Horst Domdey (Managing Director, BioM Biotech Cluster Development GmbH)
Bavarian biotechnology report – Innovations for medicine
Dr. Jens Vollmar (Head of Medical Discipline “Vaccines, travel and tropical medicine”, GlaxoSmithKline GmbH & Co. KG)
Renaissance of vaccines
Dr. Christine Günther (CEO, apceth GmbH & Co. KG)
A pioneer from the region: Cell therapy for the next generation
Moderation
Bert Fröndhoff (Chief “Chemistry and Pharma” Editor, Handelsblatt)
Speakers
Dr. Simon Moroney (CEO, Morphosys AG)
Investor Relations of biotech companies – comparison Europe and USA
Sandra Wirsching (Chief Editor, Biocom AG)
2016 – Analysis of European Biotech Companies on the Stock Markets: US vs Europe
Enno Spillner (CEO / CFO, 4SC AG)
EpiScience for Life – Cancer therapie at the most modern level
Moderation
Susanne Kutter (Journalist, Wirtschaftswoche)
Registration for the Biotech Press Lounge
Journalists and managing directors or board members of biotech, pharmaceutical and venture capital companies as well as scientists and multipliers from the industry can register for the Biotech Press Lounge.
The number of participants is limited to 100 people.
